RARE DISEASE
Alexander disease
Alexander disease
Alexander disease
Synonyms: AxD
Synonyms: AxD
Synonyms: AxD
Drug discovery
2
drugs
With orphan designations
Overview
Alexander disease is a rare, progressive leukodystrophy caused by dominant GFAP gene mutations, leading to astrocytic Rosenthal fibers and white matter degeneration. It manifests as infantile (most common), juvenile, or adult-onset forms, with symptoms including seizures, developmental regression, megalencephaly, swallowing difficulties, and spasticity. Diagnosis relies on MRI findings and genetic testing [1][5][6].
Burden
Infantile form: Median survival 14 years; adult-onset often progresses >25 years [7][9]
High care needs: 63% require feeding tubes; 47% develop scoliosis; 34% need respiratory support [7][9][13]
Economic impact: Chronic hospitalization, specialized equipment, and lost caregiver productivity [5][7][13]
Therapies
Symptomatic management: Antiseizure drugs (e.g., valproic acid, 95% effective for vomiting [3]), reflux medications, nutritional support [5][7][9]
Emerging therapies: Antisense oligonucleotides (ION373) reduce GFAP expression in trials, showing symptom reversal in preclinical models [11][14][19]
Supportive care: Multidisciplinary PT/OT/speech therapy, feeding tubes, and scoliosis/respiratory interventions [5][7][9]
Categories: rare genetic diseases, rare neurological diseases
Research Papers
106 drug discovery papers about Alexander disease, with 2 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
106 drug discovery papers about Alexander disease, with 2 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-05-13 | Industry Insights: Regulatory progress and AI-driven advances in nucleic acid therapeutics
Across March and April 2026, activity in the nucleic acid therapeutics field reflected broad regulatory momentum and continued clinical advancement across multiple RNA modalities. Regulatory highlights included US FDA Priority Review designations for Ionis' antisense oligonucleotide (ASO) zilganersen in Alexander disease, alongside EMA acceptance of GSK's marketing authorisation application for the ASO bepirovirsen in chronic hepatitis B. Clinical milestones featured first-in-human trials of novel modalities, including Alltrna's transfer RNA therapeutic AP003 and AIRNA's RNA-editing candidate AIR-001. AI-driven discovery also advanced, with Asimov launching an integrated RNA optimisation platform and ProQR partnering with Ginkgo Bioworks to scale high-throughput data generation for its RNA editing pipeline.
2026-03-04 | From scaffold to effector: reframing GFAP in neurodegeneration.
Neurodegenerative disorders impose a growing global burden, yet disease-modifying therapies remain limited. Glial fibrillary acidic protein (GFAP) has shifted from a passive astrocytic marker to an active effector that shapes neurodegenerative pathology. of Review: This review synthesizes mechanistic and translational evidence that defines GFAP as a proteoform-governed hub and highlights its value for biomarker-guided precision intervention. Key Scientific Concepts of Review: An extensive literature search across major databases was conducted using predefined keywords and strict inclusion criteria, covering mechanistic, pathological, and clinical studies. Evidence supports a GFAP proteoform code in which alternative splicing generates functionally distinct isoforms, and PTMs encode context-dependent assembly dynamics and signaling outputs. We summarize how GFAP proteoforms integrate cytoskeletal remodeling with inflammatory transcriptional programs (notably STAT3 and NF-κB), proteostasis stress, and mitochondrial dysfunction, thereby coupling astrocyte state transitions to neuronal vulnerability and synaptic impairment. Disease trajectories are context-specific: GFAP dysfunction drives primary toxicity in Alexander disease (AxD); in Alzheimer's disease (AD), isoform-specific mechanisms intersect with amyloidogenic machinery and track early preclinical astrocyte activation; and in frontotemporal dementia (FTD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), GFAP reflects inflammatory-metabolic coupling during progression. Translationally, ultrasensitive plasma assays reveal GFAP elevation years to decades before symptom onset, complementing NfL and amyloid/tau within AT(N)-oriented diagnostic frameworks. Therapeutically, we evaluate precision strategies beyond global suppression, including ASO-based modulation, targeting STAT3/NF-κB-driven reactive programs, and restoring proteostasis via chaperone/autophagy pathways. Future progress hinges on isoform-/PTM-specific probes, conformational sensors, and spatial proteomic atlases validated in prospective longitudinal cohorts. In conclusion, GFAP represents both a mechanistic driver and a scalable biomarker, offering a translationally actionable axis to advance precision medicine in neurodegeneration.
2025-12-15 | Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants.
Glial Fibrillary Acidic Protein (GFAP) is a key intermediate filament protein critical for maintaining the structural integrity and function of astrocytes in the central nervous system. Mutations in GFAP are the root cause of Alexander disease (AxD), a rare and often fatal neurodegenerative disorder characterized by elevation of GFAP levels and accumulation of GFAP in the form of Rosenthal fibers. Here, we outline a comprehensive set of experimental approaches for the biochemical characterization of GFAP and its disease-causing variants. Using optimized expression and advanced purification techniques, we achieved high yields and purity of both wild-type and mutant GFAP proteins. Biochemical assays were employed to evaluate the effects of pathogenic mutations on filament assembly, solubility, and aggregation. Additionally, we explored the role of aberrant posttranslational modifications in GFAP aggregation and their impact on filament properties. This work advances our understanding of GFAP's role in AxD and lays a foundation for developing therapeutic strategies targeting GFAP dysfunction. Furthermore, the methodologies presented here serve as valuable tools for investigating the biochemical consequences of GFAP mutations and advancing interventions for GFAP-related disorders.
2025-09-29 | Description of the Hamburg Alexander Leukodystrophy Cohort—Insights into Practical Classification and the Care Situation
Background: Alexander disease (AxD) is a rare severe leukodystrophy that has no cure to date. A pathogenic gain-of-function variant in the GFAP gene affects the astrocytes and subsequently the function of the white matter in the CNS. Methods: We retrospectively analyzed the most frequent symptoms of nine AxD cases, classified them according to published classifications, and described the need of care and support. Results: The description of the courses of disease of nine cases with AxD reflects the broad spectrum of different phenotypes of AxD, with often occurring apnoea. Data about care and support for AxD patients indicate a high and heterogeneous need of support. Treatment with steroids reduced symptoms in two patients. Some patients showed lasting improvement during their course of disease. Conclusions: The course of AxD is very heterogeneous. Thus, we extracted relevant key features to describe the severity of the disease, namely feeding problems, epilepsy, age-appropriate motor function, failure to thrive, age-appropriate language and apnoea. We recommend early evaluation for clinical care and support. For some AxD patients, treatment with steroids may alleviate symptoms. Further development of efficient treatments is necessary.
2025-08-22 | Targeting astrocytic CLC2(CLCN2) restores myelin regeneration through inhibition of SPP1/CD44 signaling pathway in leukoencephalopathy.
Accumulating myelin damage and impaired remyelination are central pathological features of leukoencephalopathies, including Multiple Sclerosis and Alexander Disease, where astrocytes play essential roles in maintaining central nervous system homeostasis and mediating astrocyte-oligodendrocyte interactions. Chloride Ion Channel 2 (ClC-2), encoded by CLCN2, is functionally expressed in astrocytes and is likely critical to white matter integrity; however, its precise roles and interactions remain unclear. Clarifying the mechanisms by which astrocytic ClC-2 influences white matter is essential for developing treatments for CLCN2-related leukoencephalopathy (CC2L) and potentially other white matter disorders. In this study, we demonstrate that dysfunctional ClC-2 in astrocytes-derived from both mouse models and human-induced pluripotent stem cells (hiPSCs)-impairs oligodendrocyte lineage cell development in vitro and delays remyelination in vivo. Transcriptomic analyses identified SPP1 as a key inhibitory factor on remyelination, secreted from ClC-2-deficient astrocytes. This inhibition was validated through astrocyte-specific modulation of SPP1 expression, where overexpression exacerbated, and downregulation alleviated, demyelination effects. Furthermore, we discovered that SPP1 upregulation in astrocytes with abnormal ClC-2 negatively impacts remyelination by interacting with CD44 on oligodendrocyte progenitor cells. Finally, we confirmed that increased SPP1 expression and the resulting suppression of oligodendrocyte lineage cell development were also present in hiPSC-derived astrocytes harboring a CLCN2 mutation from a CC2L patient. Collectively, these findings reveal that astrocytic ClC-2 is intricately linked to white matter integrity through SPP1 regulation, positioning it as a potential therapeutic target for CC2L and other leukoencephalopathies.
2026-05-13 | Industry Insights: Regulatory progress and AI-driven advances in nucleic acid therapeutics
Across March and April 2026, activity in the nucleic acid therapeutics field reflected broad regulatory momentum and continued clinical advancement across multiple RNA modalities. Regulatory highlights included US FDA Priority Review designations for Ionis' antisense oligonucleotide (ASO) zilganersen in Alexander disease, alongside EMA acceptance of GSK's marketing authorisation application for the ASO bepirovirsen in chronic hepatitis B. Clinical milestones featured first-in-human trials of novel modalities, including Alltrna's transfer RNA therapeutic AP003 and AIRNA's RNA-editing candidate AIR-001. AI-driven discovery also advanced, with Asimov launching an integrated RNA optimisation platform and ProQR partnering with Ginkgo Bioworks to scale high-throughput data generation for its RNA editing pipeline.
2026-03-04 | From scaffold to effector: reframing GFAP in neurodegeneration.
Neurodegenerative disorders impose a growing global burden, yet disease-modifying therapies remain limited. Glial fibrillary acidic protein (GFAP) has shifted from a passive astrocytic marker to an active effector that shapes neurodegenerative pathology. of Review: This review synthesizes mechanistic and translational evidence that defines GFAP as a proteoform-governed hub and highlights its value for biomarker-guided precision intervention. Key Scientific Concepts of Review: An extensive literature search across major databases was conducted using predefined keywords and strict inclusion criteria, covering mechanistic, pathological, and clinical studies. Evidence supports a GFAP proteoform code in which alternative splicing generates functionally distinct isoforms, and PTMs encode context-dependent assembly dynamics and signaling outputs. We summarize how GFAP proteoforms integrate cytoskeletal remodeling with inflammatory transcriptional programs (notably STAT3 and NF-κB), proteostasis stress, and mitochondrial dysfunction, thereby coupling astrocyte state transitions to neuronal vulnerability and synaptic impairment. Disease trajectories are context-specific: GFAP dysfunction drives primary toxicity in Alexander disease (AxD); in Alzheimer's disease (AD), isoform-specific mechanisms intersect with amyloidogenic machinery and track early preclinical astrocyte activation; and in frontotemporal dementia (FTD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), GFAP reflects inflammatory-metabolic coupling during progression. Translationally, ultrasensitive plasma assays reveal GFAP elevation years to decades before symptom onset, complementing NfL and amyloid/tau within AT(N)-oriented diagnostic frameworks. Therapeutically, we evaluate precision strategies beyond global suppression, including ASO-based modulation, targeting STAT3/NF-κB-driven reactive programs, and restoring proteostasis via chaperone/autophagy pathways. Future progress hinges on isoform-/PTM-specific probes, conformational sensors, and spatial proteomic atlases validated in prospective longitudinal cohorts. In conclusion, GFAP represents both a mechanistic driver and a scalable biomarker, offering a translationally actionable axis to advance precision medicine in neurodegeneration.
2025-12-15 | Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants.
Glial Fibrillary Acidic Protein (GFAP) is a key intermediate filament protein critical for maintaining the structural integrity and function of astrocytes in the central nervous system. Mutations in GFAP are the root cause of Alexander disease (AxD), a rare and often fatal neurodegenerative disorder characterized by elevation of GFAP levels and accumulation of GFAP in the form of Rosenthal fibers. Here, we outline a comprehensive set of experimental approaches for the biochemical characterization of GFAP and its disease-causing variants. Using optimized expression and advanced purification techniques, we achieved high yields and purity of both wild-type and mutant GFAP proteins. Biochemical assays were employed to evaluate the effects of pathogenic mutations on filament assembly, solubility, and aggregation. Additionally, we explored the role of aberrant posttranslational modifications in GFAP aggregation and their impact on filament properties. This work advances our understanding of GFAP's role in AxD and lays a foundation for developing therapeutic strategies targeting GFAP dysfunction. Furthermore, the methodologies presented here serve as valuable tools for investigating the biochemical consequences of GFAP mutations and advancing interventions for GFAP-related disorders.
2025-09-29 | Description of the Hamburg Alexander Leukodystrophy Cohort—Insights into Practical Classification and the Care Situation
Background: Alexander disease (AxD) is a rare severe leukodystrophy that has no cure to date. A pathogenic gain-of-function variant in the GFAP gene affects the astrocytes and subsequently the function of the white matter in the CNS. Methods: We retrospectively analyzed the most frequent symptoms of nine AxD cases, classified them according to published classifications, and described the need of care and support. Results: The description of the courses of disease of nine cases with AxD reflects the broad spectrum of different phenotypes of AxD, with often occurring apnoea. Data about care and support for AxD patients indicate a high and heterogeneous need of support. Treatment with steroids reduced symptoms in two patients. Some patients showed lasting improvement during their course of disease. Conclusions: The course of AxD is very heterogeneous. Thus, we extracted relevant key features to describe the severity of the disease, namely feeding problems, epilepsy, age-appropriate motor function, failure to thrive, age-appropriate language and apnoea. We recommend early evaluation for clinical care and support. For some AxD patients, treatment with steroids may alleviate symptoms. Further development of efficient treatments is necessary.
2025-08-22 | Targeting astrocytic CLC2(CLCN2) restores myelin regeneration through inhibition of SPP1/CD44 signaling pathway in leukoencephalopathy.
Accumulating myelin damage and impaired remyelination are central pathological features of leukoencephalopathies, including Multiple Sclerosis and Alexander Disease, where astrocytes play essential roles in maintaining central nervous system homeostasis and mediating astrocyte-oligodendrocyte interactions. Chloride Ion Channel 2 (ClC-2), encoded by CLCN2, is functionally expressed in astrocytes and is likely critical to white matter integrity; however, its precise roles and interactions remain unclear. Clarifying the mechanisms by which astrocytic ClC-2 influences white matter is essential for developing treatments for CLCN2-related leukoencephalopathy (CC2L) and potentially other white matter disorders. In this study, we demonstrate that dysfunctional ClC-2 in astrocytes-derived from both mouse models and human-induced pluripotent stem cells (hiPSCs)-impairs oligodendrocyte lineage cell development in vitro and delays remyelination in vivo. Transcriptomic analyses identified SPP1 as a key inhibitory factor on remyelination, secreted from ClC-2-deficient astrocytes. This inhibition was validated through astrocyte-specific modulation of SPP1 expression, where overexpression exacerbated, and downregulation alleviated, demyelination effects. Furthermore, we discovered that SPP1 upregulation in astrocytes with abnormal ClC-2 negatively impacts remyelination by interacting with CD44 on oligodendrocyte progenitor cells. Finally, we confirmed that increased SPP1 expression and the resulting suppression of oligodendrocyte lineage cell development were also present in hiPSC-derived astrocytes harboring a CLCN2 mutation from a CC2L patient. Collectively, these findings reveal that astrocytic ClC-2 is intricately linked to white matter integrity through SPP1 regulation, positioning it as a potential therapeutic target for CC2L and other leukoencephalopathies.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Alexander disease.
2 orphan drug designations for Alexander disease.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
zilganersen | oligonucleotides | FDA | 2020-09-18 | — | Ionis Pharmaceuticals |
2'-O-(2-methoxyethyl)-D-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid | oligonucleotides | EMA | 2019-10-17 | — | Ionis Development (Ireland) Limited |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.